Non-coding RNA for early diagnosis of laryngeal squamous cell carcinoma

A non-coding technology for laryngeal squamous cell carcinoma, applied in the field of biomedicine, can solve the problems of high postoperative recurrence rate and difficulty in early diagnosis of laryngeal cancer

Pending Publication Date: 2019-09-13
BEIJING MEDINTELL BIOMED CO LTD
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The reasons are mainly manifested in three aspects: First, the early clinical manifestations of laryngeal cancer are diverse, which brings great difficulty to the early diagnosis of laryngeal cancer. Most patients fail to receive timely and effective treatment in the early stage. Molecular markers are the key to improving the early diagnosis rate of laryngeal cancer
Second, the treatment of laryngeal cancer is mainly based on surgery, supplemented by radiotherapy and chemotherapy. Although partial laryngectomy and the early stage of glottic lar

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Non-coding RNA for early diagnosis of laryngeal squamous cell carcinoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1 Screening for differentially expressed molecules

[0029] 1. Research object

[0030] The cancer tissues and corresponding paracancerous tissues of 5 patients with laryngeal squamous cell carcinoma were collected. Inclusion and exclusion criteria: ①Patients have no primary tumor other than the primary tumor, and the primary tumor has not metastasized; ②No history of cardiovascular and cerebrovascular diseases such as diabetes and hypertension; ③No infectious diseases such as hepatitis, syphilis, tuberculosis, and HIV Medical history; ④ no family history of genetic diseases; ⑤ no radiotherapy, chemotherapy and biological therapy before operation.

[0031] Sampling precautions: When cutting tumor specimens, pay attention to cutting non-necrotic tumor tissue in the central area of ​​the tumor. When cutting normal adjacent tissues, try to stay away from the tumor as far as possible, and be more than 1.5cm away from the edge of the tumor. Try to cut mucosal epithe...

Embodiment 2

[0086] Example 2 Large sample verification screened out differentially expressed molecules

[0087] 1. Sample collection

[0088] According to the method of Example 1, the cancer tissues and paracancerous tissues of 30 patients with laryngeal squamous cell carcinoma were collected.

[0089] 2. Validation at the transcript level

[0090] Reagents: Reverse transcription kit (DDR037A) was purchased from Treasure Bioengineering (Dalian) Co., Ltd. SYBR Premix Ex Taq for real-time quantitative PCR (polymerase chain reaction) TM (Tli RNaseHPlus) kit was produced by Japan Takara Company.

[0091] 2.1 Extraction of total tissue RNA

[0092] Step is with embodiment 1.

[0093] 2.2 Reverse transcription

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a molecular marker which can be used for diagnosing laryngeal squamous cell carcinoma. The marker is LOC100507002. By detecting the level of the LOC100507002 in the suspected diseased tissue of a subject, the invention can judge whether the subject suffers from laryngeal squamous cell carcinoma or not or whether the subject has the risk of suffering from laryngeal squamouscell carcinoma. According to the LOC100507002, a product for diagnosing laryngeal squamous cell carcinoma by detecting the content of the LOC100507002 can be developed, and the diagnosis product can be popularized and used clinically.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to a non-coding RNA for early diagnosis of laryngeal squamous cell carcinoma. Background technique [0002] Laryngeal cancer is a common malignant tumor in the head and neck, accounting for the second place in head and neck tumors, and its incidence rate accounts for about 5% of systemic malignant tumors. Most squamous cell carcinomas originate in the vocal cords, accounting for about 60%. Huang Xinhui et al conducted a retrospective analysis on 306 cases of laryngeal malignant tumors and found that squamous cell carcinoma accounted for 99.7% of all malignant tumors, among which squamous cell carcinoma with high and moderate differentiation was the main type; the primary site of laryngeal cancer was mostly glottic type, Followed by supraglottic type, subglottic type; smoking, drinking are closely related to the occurrence of tumors. Although surgery, radiotherapy, and chemotherapy can alle...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/6886
CPCC12Q1/6886C12Q2600/158C12Q2600/178
Inventor 曹震孙耀兰
Owner BEIJING MEDINTELL BIOMED CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap